Who
Eric Venker
President & Immunovant CEO
Company insider
Files Form 4 as: President & Immunovant CEO, Roivant Sciences; Chief Executive Officer, Immunovant.
In numbers
- Trades disclosed
- 350
- Buys
- 0
- Sells
- 92
- Bought
- $0
- Sold
- $263.9M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 25 Mar 2022
- Last trade
- 20 Oct 2026
- Last filed
- 22 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Oct 2026filed 22 Oct 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $6.5M185,856 at $35.09 | filing |
| 20 Oct 2026filed 22 Oct 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $501K14,144 at $35.42 | filing |
| 2 Oct 2026filed 5 Oct 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $120K3,506 at $34.11 | filing |
| 1 Oct 2026filed 5 Oct 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code M | $1.3M92,187 at $14.46 | filing |
| 1 Oct 2026filed 5 Oct 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code D | $2.9M85,886 at $33.65 | filing |
| 1 Oct 2026filed 5 Oct 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code M | —92,187 at $0.00 | filing |
| 30 Sep 2026filed 2 Oct 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $770K200,000 at $3.85 | filing |
| 30 Sep 2026filed 2 Oct 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $7.3M200,000 at $36.62 | filing |
| 30 Sep 2026filed 2 Oct 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —200,000 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $770K200,000 at $3.85 | filing |
| 28 Aug 2026filed 1 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $5.9M166,182 at $35.63 | filing |
| 28 Aug 2026filed 1 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $1.2M33,818 at $36.44 | filing |
| 28 Aug 2026filed 1 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —200,000 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —200,000 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $770K200,000 at $3.85 | filing |
| 28 Aug 2026filed 1 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $5.9M166,182 at $35.63 | filing |
| 28 Aug 2026filed 1 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $1.2M33,818 at $36.44 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $512K13,909 at $36.84 | filing |
| 20 Aug 2026filed 24 Aug 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $512K13,909 at $36.84 | filing |
| 27 Jul 2026filed 29 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $770K200,000 at $3.85 | filing |
News
Roivant's Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)tickerreport.com · 6 Oct 2026Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares RiseROIV · rttnews.com · 21 Oct 2026Head to Head Analysis: Roivant Sciences (NASDAQ:ROIV) vs. Pharming Group (NASDAQ:PHAR)ROIV · dailypolitical.com · 14 Oct 2026Analyzing Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS)ROIV · themarketsdaily.com · 12 Oct 2026
1 headline in the last 90 days name Eric Venker; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.